Neutrophil-Predominant Bullous Pemphigoid Induced by Checkpoint Inhibitors: A Case Series.

Checkpoint inhibitors have been revolutionary in the treatment of metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma. By restricting negative feedback of T-cells, checkpoint inhibitors allow the immune system to identify and destroy malignant cells. This enhanced immune response is efficacious in the treatment of the aforementioned malignancies; however, it may lead to immune-related adverse events. Bullous pemphigoid is a well-documented cutaneous adverse reaction of checkpoint inhibitors, with a majority of cases reporting an eosinophil-predominant or mixed inflammatory infiltrate. We report two cases of neutrophil-predominant bullous pemphigoid presenting in patients on checkpoint inhibitors. This article is protected by copyright. All rights reserved.